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Introduction
Interstitial lung diseases (ILD) are defined as a variety of 
heterogeneous and diffuse parenchymal lung disorders as-
sociated with significant morbidity and mortality, sharing 
similar clinical, radiographical, physiological, or pathologi-
cal manifestations [1]. These diseases are generally thought 
to share a common pattern of physiologic abnormality, 
characterized by a restrictive ventilatory defect and reduced 
diffusing capacity for carbon monoxide (DLCO) [2, 3].
Conflicting reports have been published regarding small 
airway function using more sophisticated testing [1, 4-6]. 
Unfortunately, these abnormalities are not specific for any 
particular ILD and the magnitude of the changes varies 
widely from patient to patient. DLCO typically is reduced 
in ILD to a greater extent than the lung volume at which it is 
measured. This statement is particularly true with IPF more 
than any other ILDs [7]. 
Hypersensitivity pneumonitis (HP) and sarcoidosis are 
two entities which have as a morphological marker the epi-
thelioid granuloma. This seems to have a certain repercus-
sion over the pulmonary function tests. It is not clear whe-
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Abstract
Background: Interstitial lung diseases (ILD) are a group of disorders that are generally thought to commonly share a restrictive ventilatory defect and 
reduced diffusing capacity for carbon monoxide (DLCO).  The aim was to find distinctive features of the pulmonary function tests (PFT) results in 
different types of ILD.
Material and methods: We conducted a retrospective study of 40 consecutive patients with ILD admitted to the Institute of Pthisiopneumology, Chisinau, 
the Republic of Moldova, during January 2019 – February 2020. The cohort included 10 cases of sarcoidosis patients, 8 cases of idiopathic pulmonary 
fibrosis (IPF) patients, 7 patients with nonspecific idiopathic interstitial pneumonia, 9 cases with hypersensitivity pneumonitis (HP) and 6 histiocytosis 
cases. All patients have been evaluated by pulmonary function tests (PFT), 6 minutes walk test, Medical Research Council scale for dyspnea, etc. 
Results: Overall, we found normal mean spirometry parameters, a slightly increased mean residual volume (127.5±42.1), a mildly decreased mean total 
lung capacity (88.8±22.3) and moderately reduced DLCO (52.6±21.5). We found a dominant restrictive pattern in 75% of patients, and obstruction 
only in 7.5% when we used spirometry parameters. When we applied the bodyplethismographic values, we have found that an air-trapping pattern was 
identified in 32.5% cases of patients. This pattern has been identified in 1/3 of HP patients and in 10% of sarcoidosis patients. 
Conclusions: PFT can help identifying individual features of different types of ILD being able to show even obstructive changes in a group of diseases 
thought to be strictly restrictive.
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ther it is the granulomatous interstitial inflammation that 
imposes an obstructive defect in these diseases. Pulmonary 
function tests in HP typically demonstrate as any other ILD 
a restrictive defect, but some studies suggest obstructive, or 
mixed abnormality [8]. 
Pulmonary function tests (PFT) in sarcoidosis com-
monly reveal a restrictive pattern as well, with a reduction 
in the DLCO, although some studies suggested that airflow 
limitation may be the most common abnormality in newly 
diagnosed patients [4, 5, 9]. 
Adult Langerhans’ cell histiocytosis (Hx) is a smoke re-
lated ILD and has different stages, which start with nodu-
lar lesions, which in the end transform into cysts [10]. 
Considering this, the functional abnormalities can vary in 
correspondence with the stage and also with the morpho-
logical changes. Similar to HP and sarcoidosis, in Hx the 
inflammation and the fibrotic process has a particular pre-
dilection for the peribronchiolar region [11], this is why we 
would expect that restrictive lesions would combine with 
air-trapping or air-flow obstruction.
Considering all the above mentioned, the exact physio-
logy of pulmonary ventilation in different types of intersti-
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tial lung diseases is unclear, this is why the aim of the study 
was to find distinctive features of the pulmonary function 
tests results in different types of ILD.
Material and methods
We have performed a retrospective study based on the 
data collected from 40 consecutive medical records of pa-
tients with ILD admitted to the Phthisiopneumology Ward 
of the Chiril Draganiuc Institute of Phthisiopneumology, 
Chisinau, the Republic of Moldova, during January 2019 – 
February 2020. 
Patients who fulfilled the following criteria were con-
sidered eligible for inclusion in the study: age older than 
18; diagnosis of a specific type of ILD established after a 
multidisciplinary ILD specialists discussion based on suit-
able clinical, imaging and/or morphology criteria; ILDs 
from the following list of entities: Idiopathic pulmonary 
fibrosis (IPF), Nonspecific Interstitial Pneumonia (NSIP), 
Sarcoidosis, Hypersensitivity pneumonitis (HP), and Adult 
Langherhans’ cell Histiocytosis (Hx). Exclusion criteria 
were the following: patients with ILD and a high suspicion 
of a concomitant infectious disease (patients with positive 
sputum cultures and C reactive protein >20mg/dl); patients 
with ILD and a concomitant malignancy, patients with an 
ILD secondary to a collagen disease. 
We have collected the following data from the medical 
records: major pulmonary symptoms, comorbidities, oxy-
gen saturation (Sa02), Medical Research Council (MRC) 
scale for dyspnea, 6 minute walk test (6MWT), and pul-
monary function test results (forced expiratory volume in 1 
second (FEV1), forced vital capacity (FVC), the ratio FEV1/
FVC, residual volume (RV), total lung capacity (TLC), and 
DLCO).
The statistical analysis was performed using the soft IBM 
SPSS statistics version 25. We have expressed the results in 
median and quartiles (for non-continuous variables, such as 
the MRC score) and the continuous variables (FEV1, FVC, 
FEV1/FVC, TLC, RV, DLCO) were expressed as mean and 
standard deviation. For multiple group analysis we used 
ANOVA test in case of normally distributed variables, and 
for group discrimination the Tuckey post hock analysis was 
used. For non-parametric variables we applied the Kruskal 
Wallis test and the post hock analysis. For calculation of 
correlation between non-parametric variables we used 
Spearman rank correlation. The level for statistical signifi-
cance was p<0.05.
Results
After processing the data we have obtained 8 cases of 
IPF patients, 10 sarcoidosis patients, 7 NSIP patients, 9 
HP patients and 6 Hx patients. The mean age in our co-
hort was 58.95±14.1 years, having the oldest patients (mean 
69.7±8.3 years) in the IPF subgroup, and the youngest 
(mean 38.3±15.6 years) in the Hx group (tab. 1), p<0.001. 
In the general cohort 80% of the patients were older than 
50 years. 
Table 1








* – Hx patients were significantly younger than the rest of the 
subgroups, p<0.001
IPF – idiopatic pulmonary fibrosis, nSIP – nonspecific indiopatic 
pneumonia, HP – hypersensitivity pneumonitis, Hx – Adult 
Langerhans cell histiocytosis.
In the gender distribution, women slightly prevailed 
over men (55% vs 45%). Although the gender was distrib-
uted statistically homogenous within subgroups (p = 0.059), 
fig. 1 shows a predominance of women in the Sarcoidosis 
subgroup (7 (70%)) and in HP subgroup (8 (89%)) while in 
IPF and Hx there was a male predominance.
Fig. 1.  gender distribution through groups
 
 















Never smoker Active smoker Ex-smoker
Fig. 2.  Smoking status in patients in the general cohort and 
within subgroups
Since the study analyzes the pulmonary function test, 
presenting the smoking habits in our cohort is of great in-
terest. As it can be seen from fig. 2, the great majority of 
our patients were non-smokers (75%). When compared be-
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tween groups, there was a statistically significant difference 
of the prevalence of smokers and ex-smokers from the Hx 
subgroup (p<0.001) with the rest of them. Other prominent 
fact is that both sarcoidosis patients and HP patients are 
100% never smokers. 
Among clinical manifestations of ILD, dry cough is an 
important symptom, found in 31 (77.5%) cases. Dyspnea 
is another frequent symptom among patients with ILD. We 
have checked the impact of dyspnea in different types of ILD 
using the MRC scale. The median of MRC dyspnea score in 
the cohort was 3 [2,3]. When compared by subgroups, we 
found that patients with Hx and patients with sarcoidosis 
had the same level of dyspnea (p>0.05). Fig. 4 shows that 
the rank of dyspnea in patients with IPF, HP and NSIP is 
statistically simmilar and is the most severe. In this way, IPF 
patients presented significantly more dyspnea when com-
pared to sarcoidosis (p=0.03), or Hx patients (p=0.007). 
Similarly, HP patients complained of significantly more se-
vere dyspnea when compared to Hx patients (p=0.031) (fig. 
3 and 4).
 Fig. 3. Dyspnea scores distribution according to MRC scale 
among groups
 
Fig. 4.  Pairwise comparison of MRC scale of dyspnea  
according to groups of ILD
Weight loss of different degree can be also a symptom 
that may accompany ILD especially in episodes of exacerba-
tion. So, 25 (62.5%) patients didn’t experience any modi-
fications in their body weight. Five (12.5%) patients have 
lost less than 5 kg, 7 (17.5%) patients have lost 5-10 kg, and 
more than 10kg loss of body weight within a short period 
of time was documented in 3 cases (7.5%). Both cough and 
weight loss variables were homogenously distributed among 
groups (p>0.05).
Analyzing the spectrum of comorbidities (fig. 5), we 
found that arterial hypertension was the most frequent co-
morbidity, being registered in almost half of the study co-
hort (19 (47.5%) patients), diabetes mellitus type II (DM 
type II) was documented in 10 (25%) cases and ischemic 
heart disease in 5(12.5%). One of the most severe complica-
tions of ILDs that portends a poor prognosis is pulmonary 
hypertension (PHT), which was found in 7 (17.5%) patients 
with no predilection for any of the subgroups (p>0.05). 
Still, PHT was found more frequent in HP patients (33.3%), 
while in sarcoidosis subgroup we didn’t isolate this compli-
cation in any of patients. In fig. 5 we can see that arterial 
hypertension is a frequent comorbidity in the IPF subgroup 
of patients, probably related to the fact that these are also 
the oldest patients in our study group. The same age factor 
(younger age this time) can be attributed to the relative lack 
of comorbidities in Hx patients. There has been identified 
a statistically significant difference between the amount of 
comorbidities in IPF patients vs Hx patients (p = 0.014).
 
 
 Fig. 5. Comorbidities prevalence within subgroups 
In terms of pulmonary function tests we found nor-
mal FEV1 (80.8±21.7) and FVC mean values (78.4±21.5), 
a slightly increased mean RV (127.5±42.1), a mildly de-
creased mean TLC (88.8±22.3) and a moderately decreased 
DLCO (52.6±21.5). 
According to the ERS/ATS series task force [12], we de-
fined FEV1/FVC below 70% – as obstructive pattern, when 
above 80% – as restriction, and between 70% and 80% – as 
normal range. So, based on FEV1/FVC only, we found a 
predominant restrictive pattern present in 75% of patients 
from our cohort (fig. 6) with no significant differences 
among groups (p>0.05).
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20% 33.3% 33.3% 17.5%
87.5% 87.5%
70% 66.7% 66.7% 75%
Obstruction Normal Restriction
Fig. 6. Distribution of functional patterns based on FEV1/FVC
Similarly, we have analyzed the body-plethysmograph’s 
parameters. We have found the presence of an air-trapping 
pattern, defined as elevated RV [12] (>140% of the pre-
dicted) in 13 (32.5%) cases (fig. 7). Hx patients have shown 
a clear cut statistical difference (p<0.001) in terms of air-
trapping pattern presence, when compared especially with 
IPF patients (p<0.001) and with NSIP patients (p<0.002), 
in which this functional abnormality was absent. The other 
two diseases have demonstrated a different degree of air-
trapping pattern, with 10% in the sarcoidosis subgroup and 
up to 1/3 in HP patients. 
 







Fig. 7. Frequency of air-trapping 
DLCO is one of the most important functional param-
eters for ILDs. Even though in the general cohort the mean 
value of DLCO has demonstrated only a mild decrease, we 
wanted to find out the variation of this parameter within the 
entities included in the subgroups. 
First, we have scaled the severity of DLCO as follows: 
normal DLCO – values that range between 80 and 140% of 
the predicted, mild decrease – 80-60%, moderate decrease 
– 60-40% and severe decrease – less than 40%. In fig. 8 it is 
shown that we found 2 (5%) patients with normal DLCO in 
the general cohort, mainly sarcoidosis patients. Within the 
sarcoidosis subgroup, normal values of DLCO accounted for 
20%, while the rest 8 (80%) were patients with mild decrease 
of DLCO. The highest rate of severely decreased DLCO 
was registered in the HP subgroup, phenomenon found in 
7(78%) patients. We found a statistically significant differ-
ence in the distribution of severity of DLCO (p<0.001) be-
tween subgroups. The degree of DLCO impairment was sig-
nificantly different in sarcoidosis patients when compared 
with IPF subgroup (p=0.042) and HP patients (p<0.001), 
while IPF patients and NSIP patients had almost identical 
proportion of categories of DLCO decrease.
 
 




















normal DLCO mild decrease moderate decrease severe decrease
Fig. 8. Distribution of DLCO according to severity
After including the static pulmonary function test, we 
wanted also to analyze the features of these patients during 
exercise. So, 6MWT was the easiest test to assess. What we 
found was a mean of the predicted distance in the general 
cohort of 67.88±26.7%. So, we have set the cut-off value of 
60% of the predicted distance and divided into two catego-
ries: under 60% and above 60%. In this way, we have found 
an acceptable exercise tolerance in 29 (72.5%) cases, while 
in almost 1/3 the physical tolerance was poor. The biggest 
proportion of patients with poor exercise tolerance was in 
the HP subgroup, while the NSIP subgroup had the best 






















over 60% predicted under 60% predicted
Fig. 9. 6MWT results in the general cohort and within subgroups 
Having analyzed all these results, we wanted to find out 
if any of the clinical features of the ILD patients could re-
flect the functional abnormalities. Spearman rank correla-
tion analysis (tab. 2) showed that dyspnea score correlates 
weakly with restriction and inversely with the 6MWT re-
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sults, and also a moderate and inverse correlation with 
DLCO variations. Smoking status as it would be expected 
correlated weakly with the presence of air trapping changes. 
Moreover, the correlational analysis established a linear as-
sociation between PHT and both DLCO and 6MWT.
Table 2 
Correlation of clinical parameters with functional 
abnormalities
 Air-trapping Restriction DLCO 6MWT
Dyspnea score -0.27 0.4* - 0.57** -0.43**
Smoking status 0.33* -0.22 0.03 0.09
Cough -0.16 0.11 -0.09 0.10
PHT -0.04 -0.15 -0.43** -0.45**
 – correlation is significant at 0.05 level, ** – correlation is significant 
at 0.01 level,
PHT – pulmonary hypertension, DLCO – diffusing lung capacity for 
carbon monoxide, 6MWT – six minute walk test.
Discussion
Interstitial lung diseases commonly share a pattern 
of physiologic abnormality characterized by a restrictive 
ventilatory defect and reduced diffusing capacity. Various 
mechanisms can contribute to these changes, including loss 
of lung volume, reduced alveolar size, and increased surface 
tension because of surfactant abnormalities [13]. As a con-
sequence, static lung volumes typically are reduced in ILDs. 
Our study found that IPF and NSIP in terms of ventilatory 
changes are very similar, showing a pure restrictive defect. 
The other 3 entities (sarcoidosis, HP and Hx) besides re-
striction, showed various degrees and incidence of obstruc-
tion. Considering that these 3 diseases share a peribronchi-
olar predilection of lesions, we supposed that pathological 
changes in the lung parenchyma and the interstitial space 
may be reflected in the lung function.
Supporting data also show that airflow limitation can be 
found in sarcoidosis [4, 9] and in some smoke related in-
terstitial lung diseases, such as histiocytosis [10]. Residual 
volume is often elevated (likely related to small airways in-
volvement) in sarcoidosis, and hypersensitivity pneumoni-
tis, for example, but is normal or reduced in IPF [14]. In 
terms of gas exchange, Boros et al. stated that DLCO is re-
duced disproportionately in IPF compared with sarcoidosis, 
even at comparable lung volumes [15]. We found similar 
results, having a statistically significant difference between 
sarcoidosis and both IPF and HP subgroups, while IPF pa-
tients and NSIP patients had almost identical proportion of 
categories of DLCO decrease. 
Several authors found that in hypersensitivity pneumo-
nitis the most common finding seems to be reduced DLCO 
[16, 17]. In our HP patients we found gas exchange im-
pairment in all the cases, with about 3/4 having a severely 
decreased DLCO. Some publications state that airflow re-
duction is a common feature for HP, and that it may reflect 
bronchiolitis, which is a prominent histopathologic feature 
of acute HP, while emphysema is a common feature among 
chronic HP patients [2, 18]. Having found the functional 
air-trapping pattern in 1/3 of our HP patients, our results 
confirm this statement. Moreover, the degree of DLCO re-
duction could also be explained in our group by the highest 
prevalence of PHT, an important comorbidity which por-
tends a poor prognosis. 
Pulmonary function tests in sarcoidosis typically reveal 
a restrictive pattern as well, with a reduction in the DLCO, 
although some studies suggested that airflow limitation may 
be the most common abnormality in newly diagnosed pa-
tients attributed either to narrowing of the bronchial wall 
because of granulomatous lesions or fibrotic scarring [4, 5, 
9], compression by enlarged lymph nodes, airway distortion 
caused by pulmonary fibrosis, small airway disease, or bron-
chial hyperreactivity [4, 19, 20]. 
As we have previously stated in the cases of other enti-
ties, in Hx, as well, pulmonary function abnormalities are 
variable and depend on both the pathological lesions and 
disease duration [11]. Several studies suggest that, simi-
lar to HP and IPF, DLCO reduction in Hx patients is the 
most common functional abnormality, and can be found in 
70–90% of cases [21, 22]. Even though we have registered 
decreased DLCO in all Hx cases, the degree of severity is 
significantly different from HP and IPF, having 2/3 of pa-
tients with only mildly reduced gas exchange. In fact, in our 
cohort a common finding was air-trapping as well, found in 
all patients. This could be explained by the fact that Hx is a 
smoking related disease, and in our subgroup 100% of pa-
tients were exposed to smoke, even though studies suggest 
that the degree of airway obstruction is predominantly re-
lated to the bronchiolar location of Hx lesions and not to the 
amount of total cigarette consumption [21]. In Hx patients, 
restrictive defect seems to be quite a rare finding [22]. 
Besides the functional changes, symptoms are a valuable 
piece in the diagnostic puzzle. We found that IPF, HP and 
NSIP patients express more symptoms with more severe 
degree of breathlessness when compared to Hx and sarcoi-
dosis individuals. Our results also showed that the degree of 
dyspnea is reflected by the gas exchange impairment. 
Although we had enough patients to make comparative 
statistical analysis of the proposed data, our study limitation 
was the small amount of patients within the subgroups. 
Due to this fact, we were not able to take into consideration 
the imaging features, and to identify dominant patterns 
within the subgroups that would have reflected or possibly 
predicted the functional disturbances. 
Conclusions
Restriction is the dominant functional abnormality of 
most ILDs, but it coexists in various extents with air-trap-
ping, found especially in patients with Hx, HP and sarcoid-
osis, this finding is related probably to the bronchiolocentric 
anatomical lesions in these entities. DLCO is almost univer-
sally decreased in ILDs, with the lowest levels registered in 
HP and in IPF patients, while mildly decreased and even 
normal values can be found in sarcoidosis and in Hx. IPF, 
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HP and NSIP patients are more dyspneic, while Hx subjects 
are less symptomatic. Also, IPF patients show more comor-
bidities, while PHT as a complication is more frequently 
found in HP. The 6MWT has shown the best results in the 
NSIP patients and the worst in HP subgroup. Clinical pa-
rameters like dyspnea and PHT are directly associated with 
low DLCO and less walked distance at the 6MWT.  
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